A joint policy document on the potential impact of the United Kingdom’s exit from the European Union from eleven associations representing the European and British life science industry, including the ABPI.
This OHE Consulting report, prepared for the ABPI and the BioIndustry Association, explores the consequences of the exit of the United Kingdom and from the European Union on public health in the UK and in the EU. It also provides an estimate of the economic impact for pharmaceutical companies.
The following Executive Summary two page report and the detailed report - capture the positive approach and can do attitude of all participants and reflect the desire to make a success of the opportunities ahead of us. It’s a record of a snapshot in time of our developing thinking rather than as a...
The ABPI is calling on the UK’s political leaders to ensure that the roadmap for the UK leaving the EU secures the future of our country’s pharmaceutical industry.
The UK’s plans to leave the European Union (EU) and the EU’s single market could have serious implications for patients’ access to medicines and medical technologies.
This briefing explores how UK and EU citizens could be affected by the disruption in trade that could result from the UK’s exit from...
In a week that sees the MHRA and CRUK publish critical information about the UK’s clinical research environment post-Brexit, ABPI's Deputy Chief Scientific Officer Dr Sheuli Porkess explores what it means for the pharmaceutical industry.
Simon Stevens appeared on the Andrew Marr Show on Sunday 1 July and was asked about preparations for Brexit and contingency planning for a no-deal scenario to ensure the continued supply of medicines to the UK.
UK Marketing Authorisation Holders urged to register with SecurMed UK
The ABPI and BIA have submitted a joint submission in response to the MHRA and DHSC consultation on 'no deal' contingency legislation for medicines and devices regulation for the UK.
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.